Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs Rituximab in CD20-positive indolent B-cell NHL (China cohort of GALLIUM-like study)
CTR20130805Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), splenic marginal zone lymphoma (SMZL), nodal marginal zone B-cell lymphoma (NMZL), marginal zone B-cell lymphoma (MZL), sponsored by Roche. Started Dec 2014; status: completed.
02
Drugs
obinutuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)splenic marginal zone lymphoma (SMZL)nodal marginal zone B-cell lymphoma (NMZL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20130805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130805.